A demonstration of peristomal ulceration in the setting of nicorandil therapy

Paul McCormack, Roderick Skelly

**DESCRIPTION**

Nicorandil is a nicotinamide ester commonly prescribed for management of angina. Since the late 1990s it has been linked with drug-induced ulceration. The current British National Formulary suggests that between 1 in 10,000 and 1 in 1,000 cases may be affected.

Initially lesions were reported in the buccal cavity, subsequently throughout the gastrointestinal (GI) tract and at the anus, with a recent association to parastomal breakdown. Cases involving fistulation to adjacent organs have also been described. Metabolites of nicorandil, nicotinic acid and nicotinamide have been suggested as factors in ulcer formation, particularly with higher doses.

A 62-year-old woman on nicorandil 30 mg twice daily for angina with a history of peripheral vascular disease, systemic lupus erythematosus, chronic obstructive pulmonary disease and hypothyroidism presented with a rectovaginal fistula. She was on no other medications associated with GI complications.

Flexible sigmoidoscopy demonstrated a rectovaginal fistula. Biopsies demonstrated only granulation tissue and ulcer slough. A loop colostomy was fashioned to treat the fistula. Two months postoperatively, the patient represented with significant peristomal ulceration.

Nicorandil was considered as a potential causative agent and treatment was discontinued. No further biopsies were taken at this stage. Within a 2-month period the peristomal ulceration had healed.

The images demonstrate the significance of the peristomal disease developed while on nicorandil (figure 1) and the subsequent improvement on cessation (figure 2).

**Learning points**

▸ Nicorandil is a commonly used antianginal with recognised links to gastrointestinal and peristomal complications, a feature prescribers must consider.

▸ Higher drug doses are implicated, therefore titration should be carefully considered with appropriate patient counselling.

▸ Clinicians who investigate patients with potential gastrointestinal disease need to be aware of the now well-recognised risk profile of this drug.

**Competing interests**  None.

**Patient consent**  Obtained.

**Provenance and peer review**  Not commissioned; externally peer reviewed.

**REFERENCES**


